Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies

Bone Marrow Transplantation volume 44, pages 709–714 (2009)Cite this article

Abstract

Natural killer (NK)-cell lymphomas are aggressive. Patients with early (stage I/II) diseases respond favorably to radiotherapy and chemotherapy. Patients with relapses and advanced (stage III/IV) diseases have poor outcome. To improve treatment results, high-dose chemotherapy with hematopoietic SCT (HSCT) has been performed. A review of 57 published cases of autologous HSCT showed the status pre-HSCT as the only significant prognostic factor. HSCT at CR had the best survival. As patients achieving CR with chemotherapy and radiotherapy also have favorable outcome, a definite advantage of autologous HSCT cannot be established. Patients with advanced, relapsed or refractory diseases had dismal survivals after autologous HSCT. Allogeneic HSCT had been reported in about 30 patients, with a 2-year OS of 40%. To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined. Furthermore, clinicopathological characteristics predicting benefits from allogeneic HSCT need to be determined. HSCT is a potential option in NK-cell lymphoma. However, autologous HSCT may not be necessary for good-risk patients in CR. Whether poor risk patients will have improved outcome with autologous HSCT remains to be defined. The role of allogeneic HSCT requires more rigorous future studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC . Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. World Health Organization Classification of Tumours. IARC Press: Lyon, 2008, 285–288.

    Google Scholar 

  2. Chan JK, Jaffe ES, Ralfkiaer E, Ko YH . Aggressive NK cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. IARC Press: Lyon, 2008, 276–277.

    Google Scholar 

  3. Cheung MM, Chan JK, Wong KF . Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 2003; 40: 221–232.

    Article  PubMed  Google Scholar 

  4. Kwong YL . Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19: 2186–2194.

    Article  CAS  PubMed  Google Scholar 

  5. Oshimi K . Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007; 139: 532–544.

    Article  CAS  PubMed  Google Scholar 

  6. Chim CS, Ooi GC, Shek TW, Liang R, Kwong YL . Lethal midline granuloma revisited: nasal T/natural-killer cell lymphoma. J Clin Oncol 1999; 17: 1322–1325.

    Article  CAS  PubMed  Google Scholar 

  7. Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501–4513.

    CAS  PubMed  Google Scholar 

  8. Chim CS, Ma ES, Loong F, Kwong YL . Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein-Barr virus encoded early small RNA in detecting occult bone marrow involvement. J Clin Pathol 2005; 58: 443–445.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821–829.

    Article  CAS  PubMed  Google Scholar 

  10. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S et al. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763–770.

    Article  CAS  PubMed  Google Scholar 

  11. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54–63.

    Article  CAS  PubMed  Google Scholar 

  12. Shikama N, Izuno I, Oguchi M, Gomi K, Sone S, Takei K et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997; 204: 467–470.

    Article  CAS  PubMed  Google Scholar 

  13. You JY, Chi KH, Yang MH, Chen CC, Ho CH, Chau WK et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618–625.

    Article  PubMed  Google Scholar 

  14. Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004; 59: 1127–1137.

    Article  PubMed  Google Scholar 

  15. Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW . Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182–190.

    Article  PubMed  Google Scholar 

  16. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181–189.

    Article  PubMed  Google Scholar 

  17. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609–615.

    Article  PubMed  Google Scholar 

  18. Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349–352.

    Article  CAS  PubMed  Google Scholar 

  19. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70–77.

    Article  CAS  PubMed  Google Scholar 

  20. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216–221.

    Article  CAS  Google Scholar 

  21. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K . P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599–606.

    CAS  PubMed  Google Scholar 

  22. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351–2356.

    Article  CAS  PubMed  Google Scholar 

  23. Chan JK . The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol 2001; 19: 129–150.

    Article  CAS  PubMed  Google Scholar 

  24. Facchetti F, Jones DM, Petrella T . Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Tumours of Haematopoietic and Lymphoid Malignancies. World Health Organization Classification of Tumours. IARC Press: Lyon, 2008, 145–147.

    Google Scholar 

  25. Nawa Y, Takenaka K, Shinagawa K, Deguchi S, Matsumura N, Koyama S et al. Successful treatment of advanced natural killer cell lymphoma with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 1321–1322.

    Article  CAS  PubMed  Google Scholar 

  26. Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma 2001; 42: 1297–1303.

    Article  CAS  PubMed  Google Scholar 

  27. Nagafuji K, Fujisaki T, Arima F, Ohshima K . L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001; 74: 447–450.

    Article  CAS  PubMed  Google Scholar 

  28. Sanda T, Lida S, Ito M, Tsuboi K, Miura K, Harada S et al. Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy. Int J Hematol 2002; 75: 195–200.

    Article  PubMed  Google Scholar 

  29. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673–1676.

    Article  CAS  PubMed  Google Scholar 

  30. Koizumi K, Fujimoto K, Haseyama Y, Endo T, Nishio M, Yokota K et al. Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma. Eur J Haematol 2004; 72: 140–144.

    Article  PubMed  Google Scholar 

  31. Suzuki R, Suzumiya J, Nakamura S, Kagami Y, Kameoka JI, Sakai C et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425–431.

    Article  CAS  PubMed  Google Scholar 

  32. Kim HJ, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006; 37: 819–824.

    Article  CAS  PubMed  Google Scholar 

  33. Teshima T, Miyaji R, Fukuda M, Ohshima K . Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia. Lancet 1996; 347: 1124.

    Article  CAS  PubMed  Google Scholar 

  34. Takami A, Nakao S, Yachie A, Kasahara Y, Okumura H, Miura Y et al. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1279–1282.

    Article  CAS  PubMed  Google Scholar 

  35. Makita M, Maeda Y, Takenaka K, Shinagawa K, Sunami K, Hiramatsu Y et al. Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol 2002; 76: 94–97.

    Article  PubMed  Google Scholar 

  36. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561–567.

    Article  PubMed  Google Scholar 

  37. Lee J, Au WY, Park MJ, Suzumiya J, Nakamura S, Kameoka J et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14: 1356–1364.

    Article  PubMed  Google Scholar 

  38. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612–618.

    Article  PubMed  Google Scholar 

  39. Au WY, Pang A, Choy C, Chim CS, Kwong YL . Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004; 104: 243–249.

    Article  CAS  PubMed  Google Scholar 

  40. Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006; 24: 28–32.

    Article  CAS  PubMed  Google Scholar 

  41. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J et al. Selective apoptosis of natural killer-cell tumours by L-asparaginase. Br J Haematol 2005; 130: 860–868.

    Article  CAS  Google Scholar 

  42. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016–1020.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The author thanks Stanley Yeung for assistance in statistical analysis.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Hong Kong, Hong Kong, China

    Y-L Kwong

Authors
  1. Y-L Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y-L Kwong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwong, YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant 44, 709–714 (2009). https://doi.org/10.1038/bmt.2009.239

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.239

Keywords

This article is cited by

Search

Advanced search

Quick links